Find a Physician | How to Contribute | About Us | Clinical Trials
 
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Head and neck: Thyroid

A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies

To find out if the study drug INCB059872 is safe and may have beneficial effects in people who have different types of cancer.

Status: Accepting New Patients
Principal Investigator: Young Chae

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

The purpose of this study is to test any good and bad effects of the combination of study drugs called ipilimumab and nivolumab in treating rare cancers and cancers of unknown primary origin.

Status: Accepting New Patients
Principal Investigator: Young Chae

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients with Advanced Solid Tumor and Lymphoma Malignancies

Two of the main purposes of this study are to determine the side effects and risks of TAK-659 and the highest dose of TAK-659 that can be given to patients daily without causing side effects and risks that are too severe.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Randomized Phase II Study of Sorafenib with or without Everolimus In Patients with Radioactive Iodine Refractory H├╝rthle Cell Thyroid Cancer

The purpose of this study is to assess additional benefit of treating your cancer with the addition of Everolimus to Sorafenib and whether these two drugs together do not give serious and intolerable side effects. The addition of everolimus to the usual sorafenib might cause more shrinkage of your cancer and might prevent it from growing but it could also cause more side effects than sorafenib alone. This study will allow the researchers to know whether this treatment with 2 drugs is better, the same, or worse than the usual approach (which is sorafenib alone). To be better, the study drugs should increase the time it takes your cancer to progress by four and a half months or more compared to the usual approach. There will be about 56 people taking part in this study.

Status: Accepting New Patients
Principal Investigator: Maria Matsangou

Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy with Or without Hippocampal Avoidance In Patients with Brain Metastases

To determine whether minimizing radiation dose to the hippocampus (a brain structure that is important for memory) during whole-brain radiation can decrease the risk of cognitive side effects after radiation therapy to the brain to using the usual whole-brain radiation plus memantine (a drug that can also reduce cognitive side effects of brain radiation).

Status: Accepting New Patients
Principal Investigator: Timothy Kruser

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

last updated: Mon - September 25, 2017 - 02:00 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.